Prof. Dr. Ayşe Altıntaş became a neurology specialist (Ege University) in 1992, “associate professor” in 1997, and “professor” in 2003 (Istanbul University, Cerrahpaşa Medical Faculty). Between 1991-1992, she studied neuroimmunology under the mentor of Prof. Moses Rodriguez at the Mayo Clinic and worked on the experimental model of Multiple Sclerosis (MS). With this work, she was awarded the Eczacıbaşı Medical Incentive Award. In 2001, he worked with Prof.C.Lucchinetti and Prof. B. Weinshenker on the neuroimmunopathological mechanisms, radiological correlations and demyelination / remyelination mechanisms of MS at Mayo Clinic.
Between 2005 and 2018, she worked as a “lecturer” in “neuroscience” and “immunology” master and doctorate programs at Aziz Sancar Experimental Medicine and Research Institute.
She has been a Board member of the European Neuroimmunology School for many years, a member of the BioMS-eu working group and the coordinator of the Turkish Neurological Association’s Neuroimmunology working group. Her current Works are focused on inflammatory demyelinating diseases of the central nervous system (multiple sclerosis &neuromyelitis optica), and primarily aimed to clarify possible disease biomarkers and mechanisms at the immunopathological level by clinical and laboratory studies.
Prof. Dr. Ayşe Altıntaş has been working at Koç University Hospital Neurology Department since June 2018.
SELECTED PUBLICATIONS
1-A.Altıntaş, Z.Cai, L.Pease, M.Rodriguez. Differential expression of H-2K and H-2D in the central nervous system of mice infected with Theiler’s virus. The Journal of Immunology Sep 1, 1993;vol 151,no 5:2803-2812.
2- A.Siva, O.Kantarcı, S.Saip, A.Altıntaş, V.Hamuryudan, C.Işlak, N.Koçer, H.Yazıcı. Behçet’s Disease:Diagnostic and prognostic aspects of neurological involvement. Journal of Neurology 2001;248:95-103.
3- Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, Weigand S, Thomsen K, Mandrekar J, Altintas A, Erickson BJ, König F, Giannini C, Lassmann H, Linbo L, Pittock SJ, Brück W. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008 Jul;131(Pt 7):1759-75. doi: 10.1093/brain/awn098
4-Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, Buee L, Castellazzi M, Cepok S, Comabella M, Constantinescu CS, Deisenhammer F, Deniz G, Erten G, Espiño M, Fainardi E, Franciotta D, Freedman MS, Giedraitis V, Gilhus NE, Giovannoni G, Glabinski A, Grieb P, Hartung HP, Hemmer B, Herukka SK, Hintzen R, Ingelsson M, Jackson S, Jacobsen S, Jafari N, Jalosinski M, Jarius S, Kapaki E, Kieseier BC, Koel-Simmelink MJ, Kornhuber J, Kuhle J, Kurzepa J, Lalive PH, Lannfelt L, Lehmensiek V, Lewczuk P, Livrea P, Marnetto F, Martino D, Menge T, Norgren N, Papuć E, Paraskevas GP, Pirttilä T, Rajda C, Rejdak K, Ricny J, Ripova D, Rosengren L, Ruggieri M, Schraen S, Shaw G, Sindic C, Siva A, Stigbrand T, Stonebridge I, Topcular B, Trojano M, Tumani H, Twaalfhoven HA, Vécsei L, Van Pesch V, Vanderstichele H, Vedeler C, Verbeek MM, Villar LM, Weissert R, Wildemann B, Yang C, Yao K, Teunissen CE. Neurofilament ELISA validation.J Immunol Methods. 2010 Jan 31;352(1-2):23-31. Epub 2009 Oct 24.
5- A.Altıntaş, B.Petek, N.Işık, M.Terzi, F.Bölükbaşı, M.Tavşanlı, S.Saip, C.Boz, T.Aydın, O.Arıcı-Düz, F.Özer, A.Siva. Clinical and radiological characteristics of tumefactive demyelinating lesions:follow-up study. Multiple Sclerosis Journal 2012; 18 (10) 1448-1453
6- Charlotte Teunissen, Til Menge, Ayse Altintas, José C Álvarez- Cermeño, Antonio Bertolotto, Frode S Berven, Lou Brundin, Manuel Comabella, Matilde Degn, Florian Deisenhammer, Franz Fazekas, Diego Franciotta, Jette L Frederiksen, Daniela Galimberti, Sharmilee Gnanapavan, Harald Hegen, Bernhard Hemmer, Rogier Hintzen, Steve Hughes, Ellen Iacobaeus, Ann C Kroksveen, Jens Kuhle, John Richert, Hayrettin Tumani, Luisa M Villar, Jelena Drulovic, Irena Dujmovic, Michael Khalil and Ales Bartos. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis Journal 2013, May 21: 1-8 DOI: 10.1177/1352458513488232.
7- Altintas A, Karabudak R, Balcı BP, Terzi M, Soysal A, Saip S, Tuncer Kurne A, Uygunoglu U, Nalbantoglu M, Gozubatik Celik G, Isik N, Celik Y, Gokcay F, Duman T, Boz C, Yucesan C, Mangan MS, Celebisoy N, Diker S, Colpak Isikay MI, Kansu T, and Siva A. Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort Demographic, Clinical, and Laboratory Features. The Neurologist 2015;20: 61–66
8- Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, Höftberger R, Costa C, Comabella M, Montalban X, Tintoré M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2016 Apr 25; pii: jnnp-2015-312601
9- Tahrali I, Kucuksezer UC, Altintas A, Uygunoglu U, Akdeniz N, Aktas-Cetin E, Deniz G. Dysfunction of CD3–CD16+CD56dim and CD3–CD16–CD56bright NK cell subsets in RR-MS patients. Clin Immunol. 2018 Aug;193:88-97.
10- Leurs CE, Twaalfhoven H, Lissenberg-Witte BI, van Pesch V, Dujmovic I, Drulovic J, Castellazzi M, Bellini T, Pugliatti M, Kuhle J, Villar LM, Alvarez-Cermeño JC, Alvarez-Lafuente R, Hegen H, Deisenhammer F, Walchhofer LM, Thouvenot E, Comabella M, Montalban X, Vécsei L, Rajda C, Galimberti D, Scarpini E, Altintas A, Rejdak K, Frederiksen JL, Pihl-Jensen G, Jensen P, Khalil M, Voortman MM, Fazekas F, Saiz A, La Puma D, Vercammen M, Vanopdenbosch L, Uitdehaag B, Killestein J, Bridel C, Teunissen C. Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Mult Scler. 2019 May 8:1352458519845844.
11- Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand’Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T. Risk of secondary progressive multiple sclerosis: A longitudinal study. Mult Scler. 2019 Aug 9:1352458519868990
12- Malpas CB, Manouchehrinia A, Sharmin S, Roos I, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Eichau S, Bergamachi R, Sola P, Ferraro D, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Maison FG, Ozakbas S, Van Pesch V, Granella F, Huppert D, Pucci E, Boz C, Sidhom Y, Gouider R, Spitaleri D, Soysal A, Petersen T, Verheul F, Karabudak R, Turkoglu R, Ramo-Tello C, Terzi M, Cristiano E, Slee M, McCombe P, Macdonell R, Fragoso Y, Olascoaga J, Altintas A, Olsson T, Butzkueven H, Hillert J, Kalincik T. Early clinical markers of aggressive multiple sclerosis. Brain; 2020 May 1;143(5):1400-1413
13- Krysko KM, Graves JS, Dobson R, Altintas A, Amato MP, Bernard J, Bonavita S, Bove R, Cavalla P, Clerico M, Corona T, Doshi A, Fragoso Y, Jacobs D, Jokubaitis V, Landi D, Llamosa G, Longbrake EE, Maillart E, Marta M, Midaglia L, Shah S, Tintore M, van der Walt A , Voskuhl R, Wang Y, Zabad RK, Zeydan B, Houtchens M aND Hellwig K on behalf of the International Women in MS (iWiMS). Sex effects across the lifespan in women with multiple sclerosis. Ther Adv Neurol Disord 2020, Vol. 13: 1–30.
14- Whittam DH, Karthikeayan V, E. Gibbons E, Kneen R, Chandratre S, Ciccarelli O, Hacohen Y, de Seze J, Deiva K, Hintzen RQ, Wildemann B, Jarius S, Kleiter I, Rostasy K, Huppke P, Hemmer B, Paul F, Aktas O, Pröbstel AK, Arrambide G, Tintore M, Amato MP, Nosadini M, Mancardi MM, Capobianco M, Illes Z, Siva A, Altintas A, Akman‑Demir G, Pandit L, Apiwattankul M, Hor JY, Viswanathan S, Qiu W, Kim HJ, Nakashima I, Fujihara K, Ramanathan S, Dale RC, Boggild M, Broadley S, Lana‑Peixoto MA, Sato DK, Tenembaum S, Cabre P, Wingerchuk DM, Weinshenker BG, Greenberg B, Matiello M, Klawiter EC, Bennett JL, Wallach AI, Kister I, Banwell BL, Traboulsee A, Pohl D, Palace J, Leite MI, Levy M, Marignier R, Solomon T, 1Lim M, Huda S, Jacob A. Treatment of MOG antibody associated disorders: results of an international survey. Journal of Neurology 2020. https://doi.org/10.1007/s00415-020-10026-y